We look forward to results of this study in DME patients in 2013. The 28-day Phase 1b/2a ascending dosage study is made to evaluate the safety and efficacy of AKB-9778 in individuals with DME. The study will enroll to 24 patients at 6 sites through the entire U up.S. The primary endpoint is security with secondary efficacy endpoints predicated on decreased retinal thickness measured by OCT , improved visual acuity and selected biomarkers.. Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, announced that it offers dosed the first individual in a today Phase 1b/2a trial of AKB-9778 for the treating diabetic macular edema .Related StoriesLiposomal sizing and the Coulter theory: an interview with Professor Melvin E. KlegermanCharles Bonnet syndrome: an interview with Dr. Dominic ffytcheInner ear damage human brain warnings from nerve cells Different shades in the 3-D brain provide clues about chemical substance processes happening during a patient's migraine strike using a PET scan, or positron emission tomography, a type of medical imaging. This higher level of immersion effectively places our investigators inside the actual patient's brain image, DaSilva said. The 3-D analysis occurs in the U-M 3-D Lab, section of the U-M Library. In a study published in the American Journal of Public Wellness recently, University of Alberta experts found that up to 65 percent of Cree preschoolers in northern Quebec communities were overweight or obese.